How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS. …
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Argent BioPharma advances epilepsy strategy with CannPal acquisition
April 13, 2026 - -
Telix signs new cancer development deal with Regeneron
April 13, 2026 - - Australian Biotech -
Australia risks falling further behind on access to new medicines without action, industry warns
April 13, 2026 - - Latest News -
HTA Review timeline set to extend well into the second half of 2027
April 13, 2026 - - Latest News -
The endpoint now coming into view was, in truth, always the most likely one
April 12, 2026 - - Latest News -
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News